期刊文献+

中国前列腺癌的流行病学概述和启示 被引量:270

Epidemiology of prostate cancer in China: an overview and clinical implication
原文传递
导出
摘要 前列腺癌已经成为我国男性的常见疾病,在发达地区发病率迅速升高,在农村地区生存率较低.针对疾病的分期特点,推动前列腺癌早期诊断是改善国内前列腺癌生存率的首要步骤.我国幅员辽阔,地区经济卫生水平差异巨大,推广有选择性的前列腺癌早期诊断策略是较好的选择.因此在优化前列腺特异抗原筛查、验证推广侵袭性前列腺癌标志物两方面均应开展深入研究,除此以外,急需开展客观的前列腺癌科普和患者教育. Prostate cancer is a currently common disease in Chinese male.The incidence is increasing rapidly in urban area and the mortality is high in rural area.According to characteristics of disease stage,advancement in early diagnosis of prostate cancer is the key to improve prostate cancer survival in China.Because of the remarkable disparity in economic and health care across China's Mainland,a selective prostate cancer screen approach may be a better alternative to spread.Therefore,indepth researches in optimization of prostate specific antigen screen and validation biomarkers of aggressive prostate cancer should be advocated.Furthermore,physicians should take a more active role in population education.
作者 叶定伟 朱耀
出处 《中华外科杂志》 CAS CSCD 北大核心 2015年第4期249-252,共4页 Chinese Journal of Surgery
关键词 前列腺肿瘤 流行病学 Prostatic neoplasms Epidemiology
  • 相关文献

参考文献5

二级参考文献36

  • 1顾方六.Epidemiological survey of benign prostatic hyperplasia and prostatic cancer in China[J].Chinese Medical Journal,2000(4):11-14. 被引量:17
  • 2邵常霞,项永兵,刘振伟,高静,孙璐,方茹蓉,阮志贤,高立峰,金凡,高玉堂.上海市区泌尿系统恶性肿瘤相对生存率分析[J].中国肿瘤临床,2005,32(6):321-324. 被引量:31
  • 3Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55:74-108.
  • 4Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin, 2006, 56:106-130.
  • 5Michael PM, Bernard D, Kaill M, et al. Management of prostate cancer in China: a multicenter report of 6 institutions. J Urol, 2005, 174:1794-1797.
  • 6Murphy AM, McKiernan JM, Olsson CA. Controversies in prostate cancer screening. J Urol, 2004, 172 : 1822-1827.
  • 7Benaim EA, Pace CM, Roehrbor CG. Gleason score predicts androgen independent progression after androgen deprivation therapy. Eur Urel, 2002, 42:12-17.
  • 8Benaim EA, Pace CM, Lam PM, et al. Nadir PSA as a progression to androgeindependent prostate cancer. Urology, 2002, 59:73-77.
  • 9Siddall JK, Hetherington JW, Cooper EH, et al. Biochemical monitoring of carcinoma of prostate treated with an LRH analogue (Zoladex). Br J Urol, 1986, 58:676-679.
  • 10Mulders PF, Fernandez del MP, Theeuwes AG, et al. Value of biochemical markers in the management of disseminated prostatic cancer. Eur Urol, 1992, 21:2-7.

共引文献564

同被引文献1613

引证文献270

二级引证文献1456

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部